The SUPN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SUPN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SUPN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View SUPN Detailed Price Forecast - CNN Money | View SUPN Detailed Summary - Google Finance | ||
View SUPN Detailed Summary - Yahoo! Finance | View SUPN Stock Research & Analysis - Zacks.com |
View SUPN Trends & Analysis - Trade-Ideas | View SUPN Major Holders - Barrons | ||
View SUPN Call Transcripts - NASDAQ | View SUPN Breaking News & Analysis - Seeking Alpha | ||
View SUPN Annual Report - CompanySpotlight.com | View SUPN OTC Short Report - OTCShortReport.com | ||
View SUPN Fundamentals - TradeKing | View SUPN SEC Filings - Bar Chart | ||
View Historical Prices for SUPN - The WSJ | View Performance/Total Return for SUPN - Morningstar | ||
View the Analyst Estimates for SUPN - MarketWatch | View the Earnings History for SUPN - CNBC | ||
View the SUPN Earnings - StockMarketWatch | View SUPN Buy or Sell Recommendations - MacroAxis | ||
View the SUPN Bullish Patterns - American Bulls | View SUPN Short Pain Metrics - ShortPainBot.com |
View SUPN Stock Mentions - StockTwits | View SUPN Stock Mentions - PennyStockTweets | ||
View SUPN Stock Mentions - Twitter | View SUPN Investment Forum News - Investor Hub | ||
View SUPN Stock Mentions - Yahoo! Message Board | View SUPN Stock Mentions - Seeking Alpha |
View Insider Transactions for SUPN - SECform4.com | View Insider Transactions for SUPN - Insider Cow | ||
View SUPN Major Holdings Summary - CNBC | View Insider Disclosure for SUPN - OTC Markets | ||
View Insider Transactions for SUPN - Yahoo! Finance | View Institutional Holdings for SUPN - NASDAQ |
View SUPN Stock Insight & Charts - FinViz.com | View SUPN Investment Charts - StockCharts.com | ||
View SUPN Stock Overview & Charts - BarChart | View SUPN User Generated Charts - Trading View |
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Posted on Wednesday April 24, 2024
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to p
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Posted on Monday April 08, 2024
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
Supernus Provides Regulatory Update for SPN-830
Posted on Monday April 08, 2024
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD
Supernus to Participate in Two Upcoming Investor Conferences
Posted on Wednesday March 06, 2024
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob